ZA200600229B - Pyrrole-2,5-dithione derivatives as Liver X receptor modulators - Google Patents
Pyrrole-2,5-dithione derivatives as Liver X receptor modulatorsInfo
- Publication number
- ZA200600229B ZA200600229B ZA200600229A ZA200600229A ZA200600229B ZA 200600229 B ZA200600229 B ZA 200600229B ZA 200600229 A ZA200600229 A ZA 200600229A ZA 200600229 A ZA200600229 A ZA 200600229A ZA 200600229 B ZA200600229 B ZA 200600229B
- Authority
- ZA
- South Africa
- Prior art keywords
- pyrrole
- liver
- receptor modulators
- dithione
- derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/36—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0316237.7A GB0316237D0 (en) | 2003-07-11 | 2003-07-11 | Therapeutic agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200600229B true ZA200600229B (en) | 2007-04-25 |
Family
ID=27741986
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200600229A ZA200600229B (en) | 2003-07-11 | 2006-01-10 | Pyrrole-2,5-dithione derivatives as Liver X receptor modulators |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US20060189663A1 (xx) |
| EP (1) | EP1646625B1 (xx) |
| JP (1) | JP2007521313A (xx) |
| KR (1) | KR20060034284A (xx) |
| CN (1) | CN100478340C (xx) |
| AR (1) | AR045720A1 (xx) |
| AT (1) | ATE399776T1 (xx) |
| AU (1) | AU2004256000B2 (xx) |
| BR (1) | BRPI0412479A (xx) |
| CA (1) | CA2532068A1 (xx) |
| CO (1) | CO5640134A2 (xx) |
| DE (1) | DE602004014772D1 (xx) |
| ES (1) | ES2308205T3 (xx) |
| GB (1) | GB0316237D0 (xx) |
| HK (1) | HK1088318A1 (xx) |
| IL (1) | IL172759A0 (xx) |
| IS (1) | IS8291A (xx) |
| MX (1) | MXPA06000447A (xx) |
| NO (1) | NO20060080L (xx) |
| RU (1) | RU2006102129A (xx) |
| SA (1) | SA04250203B1 (xx) |
| TW (1) | TW200507836A (xx) |
| UA (1) | UA82108C2 (xx) |
| UY (1) | UY28407A1 (xx) |
| WO (1) | WO2005005416A1 (xx) |
| ZA (1) | ZA200600229B (xx) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0500055D0 (sv) | 2005-01-10 | 2005-01-10 | Astrazeneca Ab | Therapeutic agents 3 |
| SE0500058D0 (sv) * | 2005-01-10 | 2005-01-10 | Astrazeneca Ab | Therapeutic agents 5 |
| WO2006073363A1 (en) | 2005-01-10 | 2006-07-13 | Astrazeneca Ab | Derivatives of isothiazol-3(2h)-one 1,1-dioxides as liver x receptor modulators |
| US7989179B2 (en) * | 2005-06-28 | 2011-08-02 | Daiichi Sankyo Company, Limited | LXR ligand testing method |
| US7893085B2 (en) | 2006-08-21 | 2011-02-22 | Genentech, Inc | Aza-benzothiophenyl compounds and methods of use |
| WO2008046014A1 (en) | 2006-10-12 | 2008-04-17 | Remedy Pharmaceuticals, Inc. | Treatment of alzheimer's disease using compounds that reduce the activity of non-selective ca++- activated atp-sensitive cation channels regulated by sur1 receptors |
| US10004703B2 (en) | 2006-10-12 | 2018-06-26 | Biogen Chesapeake Llc | Treatment of alzheimer's disease using compounds that reduce the activity of non-selective CA++ activated ATP-sensitive cation channels regulated by SUR1 channels |
| US20100143270A1 (en) * | 2007-02-21 | 2010-06-10 | University Of Louisville Research Foubdation | Therapeutic cotinine compositions |
| ES2638977T3 (es) | 2007-12-04 | 2017-10-24 | Biogen Chesapeake Llc | Formulaciones y procedimientos mejorados para liofilización y liofilizados obtenidos por los mismos |
| US20110034560A1 (en) * | 2008-01-29 | 2011-02-10 | Sven Jacobson | Liquid formulations of compounds active at sulfonylurea receptors |
| EP2310373A1 (en) | 2008-07-01 | 2011-04-20 | Genentech, Inc. | Bicyclic heterocycles as mek kinase inhibitors |
| US8492427B2 (en) | 2008-07-01 | 2013-07-23 | Genentech, Inc. | Isoindolones derivatives as MEK kinase inhibitors and methods of use |
| WO2012033353A2 (ko) | 2010-09-07 | 2012-03-15 | 서울대학교 산학협력단 | 세스터터핀 화합물 및 이들 물질의 용도 |
| AU2015204572B2 (en) | 2014-01-10 | 2020-07-30 | Inspirna, Inc. | LXR agonists and uses thereof |
| WO2017123568A2 (en) | 2016-01-11 | 2017-07-20 | The Rockefeller University | Methods for the treatment of myeloid derived suppressor cells related disorders |
| US11214536B2 (en) | 2017-11-21 | 2022-01-04 | Inspirna, Inc. | Polymorphs and uses thereof |
| KR200492570Y1 (ko) | 2018-12-04 | 2020-11-05 | 박규환 | 조립식 계단장치를 위한 발판 |
| CA3161274A1 (en) | 2019-12-13 | 2021-06-17 | Stephen Wald | Metal salts and uses thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU6111699A (en) * | 1998-10-08 | 2000-05-01 | Smithkline Beecham Plc | Novel method and compounds |
| JP2004500332A (ja) * | 1999-07-08 | 2004-01-08 | テュラリク インコーポレイテッド | Ｈｄｌコレステロール値を上昇させる組成物および方法 |
-
2003
- 2003-07-11 GB GBGB0316237.7A patent/GB0316237D0/en not_active Ceased
-
2004
- 2004-06-29 TW TW093119119A patent/TW200507836A/zh unknown
- 2004-07-05 SA SA4250203A patent/SA04250203B1/ar unknown
- 2004-07-08 AT AT04749151T patent/ATE399776T1/de not_active IP Right Cessation
- 2004-07-08 CA CA002532068A patent/CA2532068A1/en not_active Abandoned
- 2004-07-08 KR KR1020067000616A patent/KR20060034284A/ko not_active Application Discontinuation
- 2004-07-08 DE DE602004014772T patent/DE602004014772D1/de not_active Expired - Fee Related
- 2004-07-08 BR BRPI0412479-0A patent/BRPI0412479A/pt not_active IP Right Cessation
- 2004-07-08 JP JP2006520139A patent/JP2007521313A/ja not_active Withdrawn
- 2004-07-08 RU RU2006102129/04A patent/RU2006102129A/ru not_active Application Discontinuation
- 2004-07-08 ES ES04749151T patent/ES2308205T3/es active Active
- 2004-07-08 AU AU2004256000A patent/AU2004256000B2/en not_active Ceased
- 2004-07-08 MX MXPA06000447A patent/MXPA06000447A/es not_active Application Discontinuation
- 2004-07-08 EP EP04749151A patent/EP1646625B1/en active Active
- 2004-07-08 CN CNB2004800197194A patent/CN100478340C/zh not_active Expired - Fee Related
- 2004-07-08 AR ARP040102418A patent/AR045720A1/es not_active Application Discontinuation
- 2004-07-08 WO PCT/SE2004/001115 patent/WO2005005416A1/en active IP Right Grant
- 2004-07-08 US US10/563,676 patent/US20060189663A1/en not_active Abandoned
- 2004-07-09 UY UY28407A patent/UY28407A1/es unknown
- 2004-08-07 UA UAA200600270A patent/UA82108C2/uk unknown
-
2005
- 2005-12-22 IL IL172759A patent/IL172759A0/en unknown
-
2006
- 2006-01-05 NO NO20060080A patent/NO20060080L/no not_active Application Discontinuation
- 2006-01-10 ZA ZA200600229A patent/ZA200600229B/xx unknown
- 2006-01-20 CO CO06005238A patent/CO5640134A2/es not_active Application Discontinuation
- 2006-02-09 IS IS8291A patent/IS8291A/is unknown
- 2006-08-07 HK HK06108722.2A patent/HK1088318A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| TW200507836A (en) | 2005-03-01 |
| AR045720A1 (es) | 2005-11-09 |
| NO20060080L (no) | 2006-02-08 |
| EP1646625A1 (en) | 2006-04-19 |
| HK1088318A1 (en) | 2006-11-03 |
| DE602004014772D1 (de) | 2008-08-14 |
| RU2006102129A (ru) | 2006-08-27 |
| WO2005005416A1 (en) | 2005-01-20 |
| CN1820003A (zh) | 2006-08-16 |
| UY28407A1 (es) | 2005-02-28 |
| GB0316237D0 (en) | 2003-08-13 |
| MXPA06000447A (es) | 2006-04-07 |
| AU2004256000A1 (en) | 2005-01-20 |
| IS8291A (is) | 2006-02-09 |
| BRPI0412479A (pt) | 2006-09-19 |
| ATE399776T1 (de) | 2008-07-15 |
| CN100478340C (zh) | 2009-04-15 |
| US20060189663A1 (en) | 2006-08-24 |
| AU2004256000B2 (en) | 2007-07-26 |
| UA82108C2 (uk) | 2008-03-11 |
| KR20060034284A (ko) | 2006-04-21 |
| CA2532068A1 (en) | 2005-01-20 |
| SA04250203B1 (ar) | 2008-02-25 |
| CO5640134A2 (es) | 2006-05-31 |
| IL172759A0 (en) | 2006-04-10 |
| ES2308205T3 (es) | 2008-12-01 |
| JP2007521313A (ja) | 2007-08-02 |
| EP1646625B1 (en) | 2008-07-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1088318A1 (en) | Pyrrole-2, 5-dithione derivatives as liver x receptor modulators | |
| IL172760A0 (en) | Pyrrole-2,5-dithione derivatives as liver x receptor modulators | |
| HK1095329A1 (en) | 3-substituted 1,5-diphenylpyrazole derivatives useful as cb1 modulators | |
| IL178767A0 (en) | Indolyl derivatives as liver - x - receptor modulators | |
| HK1092143A1 (en) | Thiazole derivatives as cannabinoid receptor modulators | |
| ZA200606974B (en) | Substituted 1,2,3,4-tetrahydrolsoquinoline derivatives | |
| EP1773768B8 (en) | Pyrrole derivatives as pharmaceutical agents | |
| HK1088003A1 (en) | 3-substituted 5,6-diaryl-pyrazine-2-carboxamide and-2-sulfonamide derivatives as cb1 modulators | |
| EP1684762A4 (en) | UREA DERIVATIVES AS MODULATORS OF KINASE | |
| EP1790650B1 (en) | NEW SUBSTITUTED IMIDAZOLE DERIVATIVES | |
| GB0400440D0 (en) | Receptor modulators | |
| AU2003259482A1 (en) | N-substituted piperidinyl-imidazopyridine compounds as 5-ht4 receptor modulators | |
| EP1699796A4 (en) | AZABICYCLIC HETEROCYCLES IN PLACE OF MODULATORS OF THE CANNABINOID RECEPTOR | |
| ZA200609234B (en) | Substituted azeplne derivatives as serotonin receptor modulators | |
| IL183140A0 (en) | Substituted benzoquinolizine derivatives | |
| EP1670483A4 (en) | 17-heterocyclic 4-azasteroid derivatives as androgen receptor modules | |
| SG121943A1 (en) | Compositions for multi-color, light activated imaging | |
| HK1101856A1 (en) | Pyrrolidine-3,4-dicarboxamide derivatives | |
| IL182739A0 (en) | Acylatednonadepsipeptides used as lysobactin derivatives | |
| PL1638940T3 (pl) | Pochodne pirolidyniowe jako ligandy dla receptora muskarynowego M3 | |
| EP1663228A4 (en) | USE OF 17-HETEROCYCLIC-4-AZASTEROIDIAN DERIVATIVES AS MODULATORS OF THE ANDROGEN RECEPTOR | |
| AU2003301299A1 (en) | Benzyl substituted (piperidin-4-yl) aminobenzamido derivatives as delta-opiod receptor modulators | |
| AP2501A (en) | Substituted pyrrole derivatives | |
| IL173337A0 (en) | Receptor | |
| ZA200606563B (en) | 3-Substituted 1,5-diphenylpyrazole derivatives useful as CB1 Modulators |